Literature DB >> 21073280

IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases.

Rui-Xue Leng1, Hai-Feng Pan, Jin-Hui Tao, Dong-Qing Ye.   

Abstract

IL-19, IL-20 and IL-24 are members of the IL-10 family of cytokines, the human IL-19, IL-20 and IL-24 genes are all located on the q32 region of chromosome 1, and the three cytokines also share a common receptor IL-20R1/IL-20R2 heterodimer. These cytokines due to the similarity and shared receptor usage, are quite overlapping in function. Recently, the available evidence has indicated that interaction of these cytokines with their receptors might exhibit pro-inflammatory effects on autoimmune diseases, particularly psoriasis and rheumatoid arthritis. Since an imbalance between anti- and pro-inflammatory cytokines contribute to the development of autoimune diseases, these cytokines may be implicated in the pathogenesis of autoimmunity. In this paper, we concisely discuss the biological features of IL-19, IL-20 and IL-24, and focus on their potential roles in autoimmune diseases. Hopefully the information obtained will lead to a better understanding of the pathogenesis and development of novel therapeutic strategies for autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073280     DOI: 10.1517/14728222.2011.534461

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  25 in total

1.  Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study.

Authors:  G Fonseca-Camarillo; J Furuzawa-Carballeda; J Granados; J K Yamamoto-Furusho
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 2.  IL-20 receptor cytokines in autoimmune diseases.

Authors:  Jun Chen; Rachel R Caspi; Wai Po Chong
Journal:  J Leukoc Biol       Date:  2018-09-07       Impact factor: 4.962

3.  Intracellular Signaling Pathways in Rheumatoid Arthritis.

Authors:  Charles J Malemud
Journal:  J Clin Cell Immunol       Date:  2013-08-19

4.  Interleukin-19 in fetal systemic inflammation.

Authors:  Zeynep Alpay Savasan; Tinnakorn Chaiworapongsa; Roberto Romero; Youssef Hussein; Juan Pedro Kusanovic; Yi Xu; Zhong Dong; Chong Jai Kim; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2012-04-03

5.  Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis.

Authors:  T W Kragstrup; M N Andersen; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2017-05-02       Impact factor: 4.330

6.  Type 2 diabetes - Tuberculosis co-morbidity is associated with diminished circulating levels of IL-20 subfamily of cytokines.

Authors:  Nathella Pavan Kumar; Vaithilingam V Banurekha; Dina Nair; Paul Kumaran; Chandra Kumar Dolla; Subash Babu
Journal:  Tuberculosis (Edinb)       Date:  2015-08-28       Impact factor: 3.131

7.  Modulation of Th1/Tc1 and Th17/Tc17 responses in pulmonary tuberculosis by IL-20 subfamily of cytokines.

Authors:  Nathella Pavan Kumar; Kadar Moideen; Vaithilingam V Banurekha; Dina Nair; Subash Babu
Journal:  Cytokine       Date:  2018-04-21       Impact factor: 3.861

Review 8.  Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.

Authors:  Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

9.  Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation.

Authors:  R Scrivo; P Conigliaro; V Riccieri; M Di Franco; C Alessandri; A Spadaro; R Perricone; G Valesini
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

Review 10.  Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes.

Authors:  Ayelet Kaminitz; Shifra Ash; Nadir Askenasy
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.